BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Paley MR, Mergo PJ, Torres GM, Ros PR. Characterization of focal hepatic lesions with ferumoxides-enhanced T2-weighted MR imaging. AJR Am J Roentgenol. 2000;175:159-163. [PMID: 10882267 DOI: 10.2214/ajr.175.1.1750159] [Cited by in Crossref: 63] [Cited by in F6Publishing: 57] [Article Influence: 2.9] [Reference Citation Analysis]
Number Citing Articles
1 Han JK, Kim SJ, Kim SH. Well-differentiated Hepatocellular Carcinoma. Korean J Hepatol 2007;13:427. [DOI: 10.3350/kjhep.2007.13.3.427] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
2 Higashihara H, Murakami T, Kim T, Hori M, Onishi H, Nakata S, Osuga K, Tomoda K, Nakamura H. Differential diagnosis between metastatic tumors and nonsolid benign lesions of the liver using ferucarbotran-enhanced MR imaging. European Journal of Radiology 2010;73:125-30. [DOI: 10.1016/j.ejrad.2008.09.028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
3 Levy AD. Noninvasive imaging approach to patients with suspected hepatobiliary disease. Techniques in Vascular and Interventional Radiology 2001;4:132-40. [DOI: 10.1016/s1089-2516(01)90019-8] [Cited by in Crossref: 8] [Article Influence: 0.4] [Reference Citation Analysis]
4 Terkivatan T, van den Bos IC, Hussain SM, Wielopolski PA, de Man RA, IJzermans JN. Focal nodular hyperplasia: lesion characteristics on state-of-the-art MRI including dynamic gadolinium-enhanced and superparamagnetic iron-oxide-uptake sequences in a prospective study. J Magn Reson Imaging 2006;24:864-72. [PMID: 16947339 DOI: 10.1002/jmri.20705] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
5 Pijl ME, Doornbos J, Wasser MN, van Houwelingen HC, Tollenaar RA, Bloem JL. Quantitative analysis of focal masses at MR imaging: a plea for standardization. Radiology. 2004;231:737-744. [PMID: 15163813 DOI: 10.1148/radiol.2313030173] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 0.8] [Reference Citation Analysis]
6 Grazioli L, Morana G, Federle MP, Brancatelli G, Testoni M, Kirchin MA, Menni K, Olivetti L, Nicoli N, Procacci C. Focal nodular hyperplasia: morphologic and functional information from MR imaging with gadobenate dimeglumine. Radiology. 2001;221:731-739. [PMID: 11719669 DOI: 10.1148/radiol.2213010139] [Cited by in Crossref: 118] [Cited by in F6Publishing: 97] [Article Influence: 5.6] [Reference Citation Analysis]
7 Kim MJ, Kim JH, Lim JS, Oh YT, Chung JJ, Choi JS, Lee WJ, Kim KW. Detection and characterization of focal hepatic lesions: mangafodipir vs. superparamagnetic iron oxide-enhanced magnetic resonance imaging. J Magn Reson Imaging 2004;20:612-21. [PMID: 15390224 DOI: 10.1002/jmri.20174] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
8 Ros PR, Mortele KJ. Hepatic imaging: An Overview. Clinics in Liver Disease 2002;6:1-16. [DOI: 10.1016/s1089-3261(03)00063-1] [Cited by in Crossref: 17] [Article Influence: 0.9] [Reference Citation Analysis]
9 Xu PJ, Yan FH, Wang JH, Shan Y, Ji Y, Chen CZ. Contribution of diffusion-weighted magnetic resonance imaging in the characterization of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver. J Comput Assist Tomogr. 2010;34:506-512. [PMID: 20657216 DOI: 10.1097/rct.0b013e3181da3671] [Cited by in Crossref: 80] [Cited by in F6Publishing: 40] [Article Influence: 6.7] [Reference Citation Analysis]
10 Li YW, Chen ZG, Wang JC, Zhang ZM. Superparamagnetic iron oxide-enhanced magnetic resonance imaging for focal hepatic lesions: Systematic review and meta-analysis. World J Gastroenterol 2015; 21(14): 4334-4344 [PMID: 25892885 DOI: 10.3748/wjg.v21.i14.4334] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
11 Levy AD. Malignant liver tumors. Clin Liver Dis 2002;6:147-64. [PMID: 11933586 DOI: 10.1016/s1089-3261(03)00070-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
12 Scharitzer M, Schima W, Schober E, Reimer P, Helmberger TK, Holzknecht N, Stadler A, Ba-ssalamah A, Weber M, Wrba F. Characterization of Hepatocellular Tumors: Value of Mangafodipir-Enhanced Magnetic Resonance Imaging. Journal of Computer Assisted Tomography 2005;29:181-90. [DOI: 10.1097/01.rct.0000156397.51640.a1] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
13 Halavaara J, Breuer J, Ayuso C, Balzer T, Bellin MF, Blomqvist L, Carter R, Grazioli L, Hammerstingl R, Huppertz A. Liver tumor characterization: comparison between liver-specific gadoxetic acid disodium-enhanced MRI and biphasic CT--a multicenter trial. J Comput Assist Tomogr. 2006;30:345-354. [PMID: 16778605 DOI: 10.1097/00004728-200605000-00001] [Cited by in Crossref: 142] [Cited by in F6Publishing: 125] [Article Influence: 8.9] [Reference Citation Analysis]
14 Bryant T, Ahmad Z, Millward-sadler H, Burney K, Stedman B, Kendall T, Vettukattil J, Haw M, Salmon AP, Cope R, Hacking N, Breen D, Sheron N, Veldtman GR. Arterialised hepatic nodules in the Fontan circulation: Hepatico-cardiac interactions. International Journal of Cardiology 2011;151:268-72. [DOI: 10.1016/j.ijcard.2010.05.047] [Cited by in Crossref: 62] [Cited by in F6Publishing: 53] [Article Influence: 5.6] [Reference Citation Analysis]
15 Li C, Chen R, Lii J, Chen W, Shih L, Zhang T, Tu H. Magnetic Resonance Imaging Appearance of Well-differentiated Hepatocellular Carcinoma: . Journal of Computer Assisted Tomography 2006;30:597-603. [DOI: 10.1097/00004728-200607000-00008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
16 Daniele Marin, Iannaccone R, Laghi A, Catalano C, Murakami T, Hori M, Kim T, Passariello R. Focal nodular hyperplasia: Intraindividual comparison of dynamic gadobenate dimeglumine- and ferucarbotran-enhanced magnetic resonance imaging. J Magn Reson Imaging 2007;25:775-82. [DOI: 10.1002/jmri.20885] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
17 Heiken JP. Distinguishing benign from malignant liver tumours. Cancer Imaging 2007;7 Spec No A:S1-14. [PMID: 17921080 DOI: 10.1102/1470-7330.2007.9084] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
18 Prasad SR, Sahani DV, Mino-kenudson M, Narra VR, Menias C, Wang HL, Middleton WD, Chintapalli KN. Benign Hepatic Neoplasms: An Update on Cross-Sectional Imaging Spectrum. Journal of Computer Assisted Tomography 2008;32:829-40. [DOI: 10.1097/rct.0b013e31815a5748] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
19 Zheng WW, Zhou KR, Chen ZW, Shen JZ, Chen CZ, Zhang SJ. Characterization of focal hepatic lesions with SPIO-enhanced MRI. World J Gastroenterol 2002; 8(1): 82-86 [PMID: 11833077 DOI: 10.3748/wjg.v8.i1.82] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
20 Lewis RB, Lattin GE Jr, Makhlouf HR, Levy AD. Tumors of the liver and intrahepatic bile ducts: radiologic-pathologic correlation. Magn Reson Imaging Clin N Am 2010;18:587-609, xii. [PMID: 21094457 DOI: 10.1016/j.mric.2010.08.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
21 Lim JH, Choi D, Cho SK, Kim SH, Lee WJ, Lim HK, Park CK, Paik SW, Kim YI. Conspicuity of hepatocellular nodular lesions in cirrhotic livers at ferumoxides-enhanced MR imaging: importance of Kupffer cell number. Radiology. 2001;220:669-676. [PMID: 11526265 DOI: 10.1148/radiol.2203001777] [Cited by in Crossref: 86] [Cited by in F6Publishing: 67] [Article Influence: 4.1] [Reference Citation Analysis]
22 Park HS, Lee JM, Kim SH, Chang S, Kim SJ, Han JK, Choi BI. Differentiation of well-differentiated hepatocellular carcinomas from other hepatocellular nodules in cirrhotic liver: value of SPIO-enhanced MR imaging at 3.0 Tesla. J Magn Reson Imaging. 2009;29:328-335. [PMID: 19161184 DOI: 10.1002/jmri.21615] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
23 Lee JM, Kim CS, Youk JH, Lee MS. Characterization of focal liver lesions with superparamagnetic iron oxide-enhanced MR imaging: value of distributional phase T1-weighted imaging. Korean J Radiol 2003;4:9-18. [PMID: 12679629 DOI: 10.3348/kjr.2003.4.1.9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
24 Zech CJ, Grazioli L, Breuer J, Reiser MF, Schoenberg SO. Diagnostic performance and description of morphological features of focal nodular hyperplasia in Gd-EOB-DTPA-enhanced liver magnetic resonance imaging: results of a multicenter trial. Invest Radiol. 2008;43:504-511. [PMID: 18580333 DOI: 10.1097/rli.0b013e3181705cd1] [Cited by in Crossref: 173] [Cited by in F6Publishing: 68] [Article Influence: 12.4] [Reference Citation Analysis]
25 Raman SS, Leary C, Bluemke DA, Amendola M, Sahani D, McTavish JD, Brody J, Outwater E, Mitchell D, Sheafor DH. Improved characterization of focal liver lesions with liver-specific gadoxetic acid disodium-enhanced magnetic resonance imaging: a multicenter phase 3 clinical trial. J Comput Assist Tomogr. 2010;34:163-172. [PMID: 20351497 DOI: 10.1097/rct.0b013e3181c89d87] [Cited by in Crossref: 50] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
26 Coenegrachts K, Matos C, ter Beek L, Metens T, Haspeslagh M, Bipat S, Stoker J, Rigauts H. Focal liver lesion detection and characterization: comparison of non-contrast enhanced and SPIO-enhanced diffusion-weighted single-shot spin echo echo planar and turbo spin echo T2-weighted imaging. Eur J Radiol 2009;72:432-9. [PMID: 18849130 DOI: 10.1016/j.ejrad.2008.09.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
27 Bluemke DA, Weber TM, Rubin D, de Lange EE, Semelka R, Redvanly RD, Chezmar J, Outwater E, Carlos R, Saini S, Holland GA, Mammone JF, Brown JJ, Milestone B, Javitt MC, Jacobs P. Hepatic MR Imaging with Ferumoxides: Multicenter Study of Safety and Effectiveness of Direct Injection Protocol. Radiology 2003;228:457-64. [DOI: 10.1148/radiol.2282012061] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 1.7] [Reference Citation Analysis]
28 Lee MH, Kim SH, Park MJ, Park CK, Rhim H. Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease. AJR Am J Roentgenol. 2011;197:W868-W875. [PMID: 22021534 DOI: 10.2214/ajr.10.6237] [Cited by in Crossref: 96] [Cited by in F6Publishing: 43] [Article Influence: 8.7] [Reference Citation Analysis]
29 Giusti S, Donati F, Paolicchi A, Bartolozzi C. Hepatocellular adenoma: imaging findings and pathological correlation. Dig Liver Dis 2005;37:200-5. [PMID: 15888286 DOI: 10.1016/j.dld.2004.04.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
30 Ogura A, Hayakawa K, Miyati T, Maeda F, Miyai A, Saeki F, Murata T. Differentiation of hepatic tumors by use of image contrast with T2-weighted MRI. Radiol Phys Technol 2009;2:54-7. [DOI: 10.1007/s12194-008-0043-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
31 Tonan T, Fujimoto K, Azuma S, Ono N, Matsushita S, Kojiro M, Hayabuchi N. Evaluation of small (<or=2 cm) dysplastic nodules and well-differentiated hepatocellular carcinomas with ferucarbotran-enhanced MRI in a 1.0-T MRI unit: utility of T2*-weighted gradient echo sequences with an intermediate-echo time. Eur J Radiol 2007;64:133-9. [PMID: 17408900 DOI: 10.1016/j.ejrad.2007.02.023] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
32 Grazioli L, Morana G, Kirchin MA, Caccia P, Romanini L, Bondioni MP, Procacci C, Chiesa A. MRI of focal nodular hyperplasia (FNH) with gadobenate dimeglumine (Gd-BOPTA) and SPIO (ferumoxides): An intra-individual comparison. J Magn Reson Imaging 2003;17:593-602. [DOI: 10.1002/jmri.10289] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 1.8] [Reference Citation Analysis]
33 Martí-bonmatí L. MR contrast agents in hepatic cirrhosis and chronic hepatitis. Seminars in Ultrasound, CT and MRI 2002;23:101-13. [DOI: 10.1016/s0887-2171(02)90031-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
34 Kim MJ, Kim JH, Choi JY, Park SH, Chung JJ, Kim KW, Mitchell DG. Optimal TE for SPIO-enhanced gradient-recalled echo MRI for the detection of focal hepatic lesions. AJR Am J Roentgenol 2006;187:W255-66. [PMID: 16928903 DOI: 10.2214/AJR.05.0706] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
35 Cho ES, Yu JS, Ahn JH, Park MS, Kim JH, Chung JJ, Kim KW. Ferucarbotran-enhanced T2-weighted magnetic resonance imaging: differentiation of hepatic cavernous hemangiomas from malignant solid lesions. Abdom Imaging 2009;34:494-501. [PMID: 18546032 DOI: 10.1007/s00261-008-9430-6] [Reference Citation Analysis]
36 Macarini L, Milillo P, Cascavilla A, Scalzo G, Stoppino L, Vinci R, Moretti G, Ettorre G. MR characterisation of dysplastic nodules and hepatocarcinoma in the cirrhotic liver with hepatospecific superparamagnetic contrast agents: pathological correlation in explanted livers. Radiol med 2009;114:1267-82. [DOI: 10.1007/s11547-009-0464-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
37 Cheng WZ, Zeng MS, Yan FH, Rao SX, Shen JZ, Chen CZ, Zhang SJ, Shi WB. Ferucarbotran versus Gd-DTPA-enhanced MR imaging in the detection of focal hepatic lesions. World J Gastroenterol 2007; 13(36): 4891-4896 [PMID: 17828821 DOI: 10.3748/wjg.v13.i36.4891] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
38 Terkivatan T, Hussain SM, De Man RA, Ijzermans JNM. Diagnosis and treatment of benign focal liver lesions. Scandinavian Journal of Gastroenterology 2009;41:102-15. [DOI: 10.1080/00365520600664391] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
39 Coenegrachts K. Magnetic resonance imaging of the liver: New imaging strategies for evaluating focal liver lesions. World J Radiol 2009; 1(1): 72-85 [PMID: 21160723 DOI: 10.4329/wjr.v1.i1.72] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
40 Chou CT, Chen RC, Chen WT, Lii JM. Percentage of signal intensity loss for characterisation of focal liver lesions in patients with chronic liver disease using ferucarbotran-enhanced MRI. Br J Radiol 2010;83:1023-8. [PMID: 20413445 DOI: 10.1259/bjr/21476692] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
41 Kim JH, Kim MJ, Suh SH, Chung JJ, Yoo HS, Lee JT. Characterization of focal hepatic lesions with ferumoxides-enhanced MR imaging: utility of T1-weighted spoiled gradient recalled echo images using different echo times. J Magn Reson Imaging 2002;15:573-83. [PMID: 11997899 DOI: 10.1002/jmri.10102] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 1.5] [Reference Citation Analysis]
42 Tanabe M, Ito K, Shimizu A, Fujita T, Onoda H, Yamatogi S, Washida Y, Matsunaga N. Hepatocellular lesions with increased iron uptake on superparamagnetic iron oxide-enhanced magnetic resonance imaging in cirrhosis or chronic hepatitis: comparison of four magnetic resonance sequences for lesion conspicuity. Magnetic Resonance Imaging 2009;27:801-6. [DOI: 10.1016/j.mri.2008.11.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
43 Heilmaier C, Lutz AM, Bolog N, Weishaupt D, Seifert B, Willmann JK. Focal liver lesions: detection and characterization at double-contrast liver MR Imaging with ferucarbotran and gadobutrol versus single-contrast liver MR imaging. Radiology 2009;253:724-33. [PMID: 19789232 DOI: 10.1148/radiol.2533090161] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
44 Kim JI, Lee JM, Choi JY, Kim YK, Kim SH, Lee JY, Han JK, Choi BI. The value of gadobenate dimeglumine-enhanced delayed phase MR imaging for characterization of hepatocellular nodules in the cirrhotic liver. Invest Radiol. 2008;43:202-210. [PMID: 18301317 DOI: 10.1097/rli.0b013e31815d6929] [Cited by in Crossref: 60] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
45 Ji H, Ros PR. Magnetic resonance imaging. Liver-specific contrast agents. Clin Liver Dis 2002;6:73-90. [PMID: 11933597 DOI: 10.1016/s1089-3261(03)00067-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
46 Mortele KJ, Ros PR. Benign liver neoplasms. Clin Liver Dis. 2002;6:119-145. [PMID: 11933585 DOI: 10.1016/s1089-3261(03)00069-2] [Cited by in Crossref: 49] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
47 Ward J, Robinson PJ. COMBINED USE OF MR CONTRAST AGENTS FOR EVALUATING LIVER DISEASE. Magnetic Resonance Imaging Clinics of North America 2001;9:767-83. [DOI: 10.1016/s1064-9689(21)00273-7] [Cited by in Crossref: 6] [Article Influence: 0.3] [Reference Citation Analysis]
48 Namkung S, Zech CJ, Helmberger T, Reiser MF, Schoenberg SO. Superparamagnetic iron oxide (SPIO)-enhanced liver MRI with ferucarbotran: efficacy for characterization of focal liver lesions. J Magn Reson Imaging 2007;25:755-65. [PMID: 17335040 DOI: 10.1002/jmri.20873] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
49 Ghazanfari MR, Kashefi M, Shams SF, Jaafari MR. Perspective of Fe3O4 Nanoparticles Role in Biomedical Applications. Biochem Res Int 2016;2016:7840161. [PMID: 27293893 DOI: 10.1155/2016/7840161] [Cited by in Crossref: 80] [Cited by in F6Publishing: 42] [Article Influence: 13.3] [Reference Citation Analysis]
50 Okada T, Sasaki F, Kamiyama T, Nakagawa T, Nakanishi K, Kobayashi R, Itoh T, Ota S, Todo S. Focal nodular hyperplasia of the liver: usefulness of superparamagnetic iron oxide–enhanced magnetic resonance imaging. Journal of Pediatric Surgery 2005;40:E21-5. [DOI: 10.1016/j.jpedsurg.2004.11.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
51 Limanond P, Raman SS, Sayre J, Lu DS. Comparison of dynamic gadolinium-enhanced and ferumoxides-enhanced MRI of the liver on high- and low-field scanners. J Magn Reson Imaging 2004;20:640-7. [DOI: 10.1002/jmri.20165] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
52 Kim SH, Choi D, Lim JH, Lee WJ, Jang HJ, Lim HK, Lee SJ, Cho JM, Kim SK, Kim GC. Optimal pulse sequence for ferumoxides-enhanced MR imaging used in the detection of hepatocellular carcinoma: a comparative study using seven pulse sequences. Korean J Radiol 2002;3:87-97. [PMID: 12087198 DOI: 10.3348/kjr.2002.3.2.87] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.1] [Reference Citation Analysis]
53 Lutz AM, Willmann JK, Goepfert K, Marincek B, Weishaupt D. Hepatocellular carcinoma in cirrhosis: enhancement patterns at dynamic gadolinium- and superparamagnetic iron oxide-enhanced T1-weighted MR imaging. Radiology. 2005;237:520-528. [PMID: 16192317 DOI: 10.1148/radiol.2372041183] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 2.8] [Reference Citation Analysis]
54 Kumano S, Murakami T, Kim T, Hori M, Okada A, Sugiura T, Noguchi Y, Kawata S, Tomoda K, Nakamura H. Using superparamagnetic iron oxide-enhanced MRI to differentiate metastatic hepatic tumors and nonsolid benign lesions. AJR Am J Roentgenol 2003;181:1335-9. [PMID: 14573430 DOI: 10.2214/ajr.181.5.1811335] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 2.2] [Reference Citation Analysis]
55 van Aalten SM, Witjes CD, de Man RA, Ijzermans JN, Terkivatan T. Can a decision-making model be justified in the management of hepatocellular adenoma? Liver Int. 2012;32:28-37. [PMID: 22098685 DOI: 10.1111/j.1478-3231.2011.02667.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
56 Li CS, Chen RC, Tu HY, Shih LS, Zhang TA, Lii JM, Chen WT, Duh SJ, Chiang LC. Imaging well-differentiated hepatocellular carcinoma with dynamic triple-phase helical computed tomography. Br J Radiol. 2006;79:659-665. [PMID: 16641423 DOI: 10.1259/bjr/12699987] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.1] [Reference Citation Analysis]
57 Morana G, Grazioli L, Testoni M, Caccia P, Procacci C. Contrast Agents for Hepatic Magnetic Resonance Imaging: . Topics in Magnetic Resonance Imaging 2002;13:117-50. [DOI: 10.1097/00002142-200206000-00002] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
58 Kim MJ, Kim JH, Chung JJ, Park MS, Lim JS, Oh YT. Focal hepatic lesions: detection and characterization with combination gadolinium- and superparamagnetic iron oxide-enhanced MR imaging. Radiology. 2003;228:719-726. [PMID: 12881583 DOI: 10.1148/radiol.2283020735] [Cited by in Crossref: 59] [Cited by in F6Publishing: 55] [Article Influence: 3.1] [Reference Citation Analysis]